ResMed Inc.'s (NYSE: RMD) adjusted earnings per share in the fourth quarter of fiscal 2024 were $2.08, up 30% year over year. The metric beat the Zacks Consensus Estimate by 2.5%. The adjustments include certain non-recurring expenses/benefits like the amortization of acquired intangibles, restructuring and masks with magnet field safety notification expenses, among others. GAAP EPS in the reported quarter was $1.98, up 26.9% from the year-ago quarter. For the full year, the adjusted EPS of $7.72 topped the Zacks Consensus Estimate by 0.3%. The metric increased 19.9% from the fiscal 2023 adjusted figure. Revenues On a reported basis, fiscal fourth-quarter revenues increased 9% year over year (up 10% at the constant exchange rate or CER) to $1.22 billion. The figure topped the Zacks Consensus Estimate by 0.7%. Full-year revenues were $4.69 billion, a 10.9% improvement on a reported basis from fiscal 2023 (up 11% at CER). The metric came almost in line with the Zacks Consensus Estimate. A Closer View of the Q4 Top Line Total Sleep and Respiratory Care revenues improved 9% (up 9% at CER) from the prior-year period to $1.07 billion. This also topped our model's projected revenues of $1.04 billion. Software-as-a-Service (SaaS) revenues grew 10% year over year to $151.9 million, which fell short of our model's projection of $154.2 million. Revenues in the combined Europe, Asia and other markets rose 7% on a reported basis (up 8% at CER) to $343.9 million. Our model had anticipated $324.7 million. ResMed Inc. Price, Consensus and EPS Surprise ResMed Inc. price-consensus-eps-surprise-chart | ResMed Inc. Quote In the United States, Canada and Latin America, revenues were $727.4 ...